News
Public · Published
Buy Jupiter Life Line Hospitals; target of Rs 340: Choice Institutional Equities
Choice Institutional Equities retained a BUY rating on Jupiter Life Line Hospitals but cut its target price to Rs 340 from Rs 410, citing higher debt to fund expansion. It expects revenue, EBITDA and profit to grow strongly through FY26–29E.
Published:
Updated:
What happened
Choice Institutional Equities retained a BUY rating on Jupiter Life Line Hospitals but cut its target price to Rs 340 from Rs 410, citing higher debt to fund expansion. It expects revenue, EBITDA and profit to grow strongly through FY26–29E.
Confirmed
Global impact / market context
A lower target price means the broker sees less upside than before, even while keeping its BUY rating. Higher borrowed money for new hospitals raises interest costs, which reduces profit, so the company must grow fast enough to offset that added expense.
Analyst inference
The report ties growth to new hospitals in Dombivli, Pune South, Mira-Bhayandar and BKC, plus more complex treatments at existing sites. Investors are weighing this expansion capacity against the debt taken on, which explains the target cut despite unchanged growth expectations.
Analyst inference
What to watch
- Watch how quickly the Dombivli hospital fills up and whether utilisation improves across established hospitals, since the report names these as drivers of sustained growth. Confirmed
- Track progress on the planned Pune South, Mira-Bhayandar and BKC expansions, because delays or cost overruns would weaken the capacity-led growth the broker expects. Proposed
- Monitor debt levels and interest costs tied to funding expansion, since higher borrowing was cited as the reason profit estimates and the target price were reduced. Analyst inference
Evidence
- Original source link unavailable